A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.
April 14, 2021 — SenseTime, a world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solution can quickly triage normal and abnormal scans from chest X-ray screening and accurately detect various chest diseases on the abnormal ones, effectively improving the efficiency of large-scale physical examination and regular clinical diagnosis.
The CE marks means that the software can be commercialised across the European Union under the European Union Medical Device Regulation (MDR), as well as other markets where it is recognised. The certification of SenseCare-Chest DR Pro marks another milestone for SenseTime to introduce its AI medical solutions for both computed tomography (CT) and digital radiography (DR) to international markets after its SenseCare-Lung Pro medical solution was granted the CE mark last year. It means that SenseTime's AI medical solutions can provide comprehensive support with an international standard to medical institutions around the world for chest diseases based on CT and DR imaging modalities.
As a routine part of medical examinations, chest x-rays (CXR) play an essential role in the early detection of chest diseases due to its accessibility and low-dose radiation exposure. However, the large quantity of CXR images generated daily leads to the heavy workload of radiologists who need to manually review and analyse the images. Misdiagnosis may also occur due to the high complexity of the body parts screened in CXR, which may present a risk to the health of patients.
To assist medical professionals conducting CXR, the SenseCare-Chest DR Pro was developed based on SenseTime's proprietary deep-learning technologies. Through learning and training with mass chest X-ray images, the software can quickly classify normal and abnormal CXR images. Concurrently, it detects and locates lesions or abnormalities for multiple diseases including pneumonia, tuberculosis, pneumothorax, pleural effusion, cardiomegaly and rib fractures. The software also automatically generates precise quantitative analysis and text descriptions. The whole process is completed within seconds, significantly improving the efficiency of doctors' diagnosis.
"We have been dedicated to developing AI tools for improving diagnosis accuracy and efficiency for years. By obtaining the CE mark for both CT and DR solutions, we hope to support the work of medical professionals with its comprehensive AI-powered chest diagnostic solutions in more and more markets globally," said Zhang Shaoting, M.D., Vice President and Deputy Head of Research at SenseTime.
"As pneumonia and lung cancer remain in the top 10 causes of death in Malaysia, there is a pressing need for diagnostic assistance software such as SenseTime's DR and CT solutions to support medical professionals in the early detection of such chest diseases. Malaysia seeks to improve both the quality and efficiency of its medical services as part of its efforts to digitalise its healthcare sector. At SenseTime, we are committed to supporting these efforts through our suite of SenseCare AI capabilities in Malaysia and the Southeast Asia region," said Mr. Martin Huang, Managing Director of SenseTime International Pte. Ltd.
SenseCare-Chest DR Pro is one of several applications in SenesTime's SenseCare platform, an AI-powered platform which offers an array of healthcare applications. Currently, the SenseCare platform encompasses up to 13 body parts and organs, covering chest, cardiovascular, liver, pathology, orthopedics and radiotherapy. It can assist doctors throughout the clinical process, from diagnosis and 3D surgery planning to rehabilitation tracking to meet the demands of various departments including radiology, pathology, cardiology, orthopedic, radiotherapy, etc.
For more information: www.sensetime.com/me-en
February 16, 2026 
